Simplify Logo

Full-Time

Associate Director

Immuno-Oncology

Confirmed live in the last 24 hours

Legend Biotech

Legend Biotech

1,001-5,000 employees

Develops and commercializes cell therapies

Biotechnology
Healthcare

Senior

Middlesex, NJ, USA

Category
Computational Biology
Biology Lab & Research
Biology & Biotech
Requirements
  • Education: Ph.D. in a relevant scientific discipline (e.g., immunology, cell biology, molecular biology, virology) with a minimum of 6 years of industry experience.
  • Experience: - Proven track record in cellular immunotherapy, particularly in CAR-T cell therapy and gene therapy.
  • Experience with in vivo CAR-T and preclinical studies.
  • Excellent leadership, communication, and project management skills.
Responsibilities
  • Provide strategic direction for in vivo CAR-T cell therapy development. Work with team members and cross-functional teams include research, clinical, and regulatory teams to ensure alignment and successful execution of the program.
  • Stay abreast of the latest advancements in in vivo CAR-T cell therapy.
  • Independently design and execute experiments, document, and interpret scientific results, present the data to cross-functional teams
  • In vivo study design and assay development. NHP study experience is a plus.
  • Can work in lab and manage projects to meet timeline in a fast-paced environment.
  • Foster a collaborative environment that encourages innovation and excellence.

Legend Biotech develops and sells cell therapies aimed at treating serious diseases, particularly cancers like hematological malignancies and solid tumors. Their approach is technology agnostic, allowing them to explore various methods to find effective treatments. The company operates in the personalized medicine sector, focusing on discovering, developing, and bringing new therapies to market. They generate revenue through licensing and selling their therapies, including CAR-T therapies, which involve modifying a patient's own cells to combat cancer. Unlike many competitors, Legend Biotech emphasizes transparency with investors, regularly updating them on financial results and business developments. Their goal is to provide effective treatments for hard-to-treat diseases through innovative cell therapy solutions.

Company Stage

IPO

Total Funding

$750.5M

Headquarters

Franklin Township, New Jersey

Founded

2014

Growth & Insights
Headcount

6 month growth

20%

1 year growth

44%

2 year growth

101%
Simplify Jobs

Simplify's Take

What believers are saying

  • Legend Biotech's recent European Commission approval for CARVYKTI® positions it as a leader in the multiple myeloma treatment market.
  • Strategic partnerships, such as the one with MaxCyte, enhance Legend Biotech's capabilities in cell engineering and expand its technological reach.
  • The company's commitment to transparency and investor relations, demonstrated through regular financial updates, fosters investor confidence and long-term stability.

What critics are saying

  • The competitive landscape in cell therapy and personalized medicine is intense, requiring continuous innovation to maintain market position.
  • Regulatory hurdles and the need for extensive clinical trials can delay the commercialization of new therapies, impacting revenue streams.

What makes Legend Biotech unique

  • Legend Biotech's technology-agnostic approach allows it to explore multiple innovative therapies, unlike competitors who may focus on a single technology.
  • The company's comprehensive business model, from discovery to commercialization, ensures control over the entire treatment lifecycle, providing a competitive edge.
  • Legend Biotech's strong focus on CAR-T therapies, particularly for hematological malignancies and solid tumors, sets it apart in the personalized medicine sector.

Help us improve and share your feedback! Did you find this helpful?